Dup 753 prevents the development of puromycin aminonucleoside-induced nephrosis.
The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day. The results suggest a possible involvement of the renin-angiotensin system in the development of puromycin aminonucleoside-induced nephrosis.
Yayama
K
K
Department of Pharmacology, Faculty of Pharmaceutical Sciences, Kobe-Gakuin University, Japan.
Kawao
M
M
Tujii
H
H
Itoh
N
N
Okamoto
H
H
D000804:Angiotensin II / Q000037:antagonists & inhibitors*; D000818:Animals; D001713:Biphenyl Compounds / Q000627:therapeutic use*; D001806:Blood Urea Nitrogen; D002784:Cholesterol / Q000097:blood; D007093:Imidazoles / Q000627:therapeutic use*; D019808:Losartan; D008297:Male; D009401:Nephrosis / Q000139:chemically induced / Q000517:prevention & control*; D011692:Puromycin Aminonucleoside / Q000037:antagonists & inhibitors* / Q000633:toxicity; D051381:Rats; D017207:Rats, Sprague-Dawley; D012084:Renin-Angiotensin System / Q000187:drug effects; D013777:Tetrazoles / Q000627:therapeutic use*
D001713:Biphenyl Compounds; D007093:Imidazoles; D013777:Tetrazoles; D000804:Angiotensin II; D011692:Puromycin Aminonucleoside; D002784:Cholesterol; D019808:Losartan